Authors
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two DecadesPostoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Latest:
Career Options for Graduating Oncology Fellows at the NIH and FDAPeter J. DeMaria, MD and Jennifer J. Gao, MD shed light on how graduating fellows seeking a rewarding and intellectually challenging career on the frontier of cancer drug development could be well served to consider a position of federal service at the NIH or FDA.
Latest:
Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast CancerFoluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Rapid Readouts: Final Analysis Results From the Phase 3 TITAN StudyKim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.
Latest:
Abiraterone Acetate/Prednisone/Apalutamide Maintains HRQOL Outcomes in Prostate CancerAbiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.
Latest:
Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer SurvivorsKelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.
Latest:
Dr. Rocconi on the Impact of the SORAYA Trial in FRα+ Ovarian Cancer TreatmentRodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.
Latest:
Dr. Oliveira on the Examination of Camizestrant Vs Fulvestrant in ER+/HER2- Breast CancerMafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.
Latest:
Dr Mitzman on the Use of Adjuvant Atezolizumab After Chemotherapy in Resectable NSCLCBrian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.
Latest:
Trastuzumab Deruxtecan in the Neoadjuvant SettingClosing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.
Latest:
Dr. Mian on the Investigation into the Synchronous Up-front Setting of Metastatic Prostate CancerOmar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.
Latest:
Dr. Dorritie on Determining Transplant Eligibility in Multiple MyelomaKathleen A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.
Latest:
ESMO 2021 Updates in Gastric Cancer and Colorectal CancerSam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.
Latest:
Kay Macleod Named Associate Director for Basic Sciences for the Cancer CenterKay Macleod, PhD, has been appointed as the associate director for Basic Sciences for the University of Chicago Medicine Comprehensive Cancer Center.
Latest:
Dr. Garg on the Need for Novel Imaging Techniques in nmCRPCNatasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.
Latest:
Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health DisparitiesHenry Ford Health + Michigan State University Health Sciences announced its funding of 5 cancer research grants of up to $100,000 each. These 5 grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.
Latest:
Dr. Strickler on the Results of Tucatinib Monotherapy in HER2+ CRCJohn H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two DecadesPostoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Latest:
Gymnastics Makes Me a Better OncologistValentina Baez Sosa, MD, shares how her early life experiences in gymnastics and coaching have helped her become a better hematology/oncology physician.
Latest:
Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast CancerJudy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.
Latest:
Dr. Kindsfather on the Evolution of Reflex Testing in Lung CancerScott K. Kindsfather, MD, discusses the evolution of reflex testing in lung cancer.
Latest:
Dr Phillips on the Use of Bispecific Antibodies and CAR T-Cell Therapy in MCL and FLTycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.
Latest:
Key Takeaways From DiscussionPhysicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.
Latest:
ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health PolicyThe Association of Community Cancer Centers announced that Matt Devino, MPH has joined the organization as Director, Cancer Care Delivery and Health Policy.
Latest:
Unmet Needs and Future Perspectives in the NSCLC Treatment LandscapeLooking to the future, a panel of experts offer closing remarks on promising developments and unmet needs in the treatment of NSCLC.
Latest:
Future Directions in Precision Medicine: An Evolving Treatment LandscapeClosing out their discussion on biomarkers and precision medicine in cancer care, key opinion leaders look toward future evolutions in the oncology landscape.
Latest:
Dr Sun on Ongoing Research Efforts Examining Clonal Hematopoiesis in RCCMaxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.
